Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
8
Expiration
Dec 4, 2026
DTE
21d
Moneyness
ITM
Intrinsic
$1.99
IBRX 8 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.50 | +42.86% | 20 | 158 |
| Nov 20, 2026 | 7d | $0.80 | +5.26% | 89 | 3,675 |
| Nov 27, 2026 | 14d | $1.04 | +0.00% | 57 | 116 |
| Dec 4, 2026 | 21d | $1.00 | -13.04% | 5 | 138 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | $1.28 | -7.91% | 15 | 1,566 |
| Dec 24, 2026 | 41d | — | — | 0 | 50 |
| Dec 31, 2026 | 48d | — | — | 0 | 2 |
| Mar 19, 2027 | 126d | $1.90 | +22.58% | 25 | 737 |
| Apr 16, 2027 | 154d | $1.59 | +0.00% | 1 | 1 |
| May 21, 2027 | 189d | $1.97 | +15.88% | 10 | 44 |
IBRX Nearby Strikes · Dec 4, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5 P | — | — | 0 | 0 | OTM |
| 5.5 P | $0.23 | +0.00% | 1 | 35 | OTM |
| 6 P | $0.30 | +0.00% | 4 | 11 | OTM |
| 6.5 P | $0.87 | +0.00% | 3 | 8 | ITM |
| 7 P | $0.63 | +23.53% | 10 | 20 | ITM |
| 7.5 P | $1.00 | +11.11% | 2 | 1,106 | ITM |
| 8 P | $1.00 | -13.04% | 5 | 138 | ITM |
| 8.5 P | $1.30 | +30.00% | 11 | 22 | ITM |
| 9 P | $1.43 | -35.87% | 5 | 15 | ITM |
| 9.5 P | $2.25 | +0.00% | 8 | 8 | ITM |
| 10 P | $2.06 | +28.75% | 1 | 54 | ITM |
| 10.5 P | $3.00 | +0.00% | 10 | 6 | ITM |
| 11 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.